

## Special Issue

# Perspectives of Immunotherapy in Tumors of the Gastrointestinal Tract

### Message from the Guest Editor

The use of immune-based therapies such as immune checkpoint inhibitors (ICIs) has become a standard therapy in various cancer types. The therapeutic application of monoclonal antibodies targeting inhibitory pathways such as programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) and CTLA-4 has recently been shown to generate meaningful improvements in clinical outcomes, as well as in cancers of the gastrointestinal tract (mainly esophageal and gastric cancer, and colorectal cancer with microsatellite instability). We welcome submissions of research and review articles on the molecular mechanisms that contribute to the response to immune-based therapies in cancer of the gastrointestinal tract to bring together expert opinions and new advances from across the field in a Special Issue of *Cancers*. We welcome submissions that cover any relevant topic, including the role of immunotherapy, potential predictive factors, the role of gut microbiota, and new therapeutic opportunities including new drug combinations.

### Guest Editor

Dr. Gianluca Masi

Department of Translational Research and New Technologies in Medicine, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, 56121 Pisa, Italy

### Deadline for manuscript submissions

closed (20 August 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/71243](https://mdpi.com/si/71243)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)